U.S. Group Challenges Gilead’s Hepatitis C Drug Patents In 5 Countries
Reuters: Gilead patents on costly hepatitis C drug challenged in five countries
“A U.S. group is trying to block patents in five countries for Gilead Sciences Inc.’s costly hepatitis C drug Sovaldi, in a bid to give almost 60 million afflicted people access to cheaper generic versions. In Argentina, Brazil, China, Russia, and Ukraine, challenges have been filed against Gilead’s patents or patent applications, the New York-based Initiative for Medicines, Access & Knowledge, or I-MAK, said on Wednesday…” (Pierson, 5/20).
The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.